Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 16 小时前评分60
正文 · 原文
Tomorrow! Don’t miss Dr. Sara Tolaney (@stolaney1) at #ESMO26 as she discusses #ADC strategies in HER2-positive #BreastCancer across the first-line metastatic and early disease settings. 🗓️Friday, October 23 ⏰ 09:45 - 11:15 CEST | 3:45 - 5:15 AM EST 📍 Pamplona Auditorium, Hall 5
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT05113251NCT05113251按 - **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer 对上
- **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer读摘要原文 →来源：Dana-Farber’s Breast Oncology Center · x.com